EU/3/16/1770

Table of contents

About

On 18 November 2016, orphan designation (EU/3/16/1770) was granted by the European Commission to Minoryx Therapeutics S.L., Spain, for 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride (also known as MIN-102) for the treatment of adrenoleukodystrophy.

Key facts

Active substance
5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride
Disease / condition
Treatment of adrenoleukodystrophy
Date of first decision
18/11/2016
Outcome
Positive
EU designation number
EU/3/16/1770

Sponsor's contact details

Minoryx Therapeutics S.L.
Permanent address of sponsor:Av. Ernest LLuch 32
08302 Mataró (Barcelona)
Spain
Tel. +34 93 702 19 75
E-mail: info@minoryx.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating